An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the fda combined spontaneous reporting system/adverse event reporting system-Reference-Cited by-同舟云学术

An evaluation of potential signals for ventricular arrhythmia and cardiac arrest with dolasetron, ondansetron, and granisetron in the fda combined spontaneous reporting system/adverse event reporting system

Published:2005-09 Issue:5 Volume:66 Page:409-419
ISSN:0011-393X
Container-title:Current Therapeutic Research
language:en
Short-container-title:Current Therapeutic Research

Author:

Schnell Frederick M.,Coop Andrew J.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference39 articles.

1. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest;Algra;Circulation,1991

2. Drug induced QT prolongation and torsades de pointes;Yap;Heart,2003

3. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels;Kuryshev;J Pharmacol Exp Ther.,2000

4. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer;Hesketh;J Clin Oncol.,1996

5. Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women;Keung;Biopharm Drug Dispos.,1997

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medical perspectives on pediatric sports medicine–Selective topics;Disease-a-Month;2022-11

2. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist;Journal of Anesthesia;2017-02-22

3. Severe Proarrhythmic Potential of the Antiemetic Agents Ondansetron and Domperidone;Cardiovascular Toxicology;2017-02-09

4. Rolapitant for the prevention of delayed nausea and vomiting over initial and repeat courses of emetogenic chemotherapy;Expert Review of Clinical Pharmacology;2016-12-15

5. Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art;Critical Reviews in Oncology/Hematology;2016-06